Drilldown: Medicines
More actions
Use the filters below to narrow your results.
generic:
None (3) ·
3-MMC (1) ·
Asenapine (1) ·
Butylone (1) ·
Cathinone (1) ·
Chlorpromazine (1) ·
Clozapine (1) ·
Droperidol (1) ·
Ephylone (1) ·
Ethcathinone (1) ·
Ethylone (1) ·
Fluphenazine (1) ·
Hexedrone (1) ·
Iloperidone (1) ·
Loxapine (1) ·
Lurasidone (1) ·
Mephedrone (1) ·
Methcathinone (1) ·
Methylone (1) ·
Mexedrone (1) ·
Molindone (1) ·
N-Ethylhexedrone (1) ·
N-Ethylpentedrone (1) ·
Paliperidone (1) ·
Pentedrone (1) ·
Perphenazine (1) ·
Pimozide (1) ·
Prochlorperazine (1) ·
Thioridazine (1) ·
Thiothixene (1) ·
Trifluoperazine (1) ·
Ziprasidone (1)
brand:
None (14) ·
Caplyta (1) ·
Clozaril (1) ·
Compazine (1) ·
Fanapt (1) ·
Geodon (1) ·
Inapsine (1) ·
Invega (1) ·
Latuda (1) ·
Loxitane (1) ·
Mellaril (1) ·
Moban (1) ·
Navane (1) ·
Orap (1) ·
Prolixin (1) ·
Rexulti (1) ·
Saphris (1) ·
Stelazine (1) ·
Thorazine (1) ·
Trilafon (1) ·
Vraylar (1)
classes: (Click arrow to add another value)
mechanism:
None (2) ·
Butyrophenone D2 antagonist (1) ·
Cathinone analogue; monoamine reuptake inhibitor (2) ·
D2 receptor antagonist; also H1, alpha-1, muscarinic antagonist (1) ·
D2/5-HT2A antagonist (1) ·
D2/5-HT2A antagonist; 5-HT7 antagonist (1) ·
D2/5-HT2A antagonist; active metabolite of risperidone (1) ·
D2/5-HT2A antagonist; SRI and NRI (1) ·
Dibenzoxazepine D2/5-HT2 antagonist (1) ·
Dihydroindolone D2 antagonist (1) ·
Diphenylbutylpiperidine D2 antagonist (1) ·
Monoamine releasing agent (4) ·
Monoamine releasing agent; active ingredient in khat (1) ·
Multi-receptor antagonist (D2, 5-HT2A, H1, alpha) (1) ·
Multi-receptor antagonist; low D2 affinity (1) ·
Norepinephrine and dopamine releasing agent (1) ·
Norepinephrine/dopamine releasing agent (1) ·
Norepinephrine/dopamine reuptake inhibitor (1) ·
Partial agonist at D2 and 5HT1A. Antagonist at 5HT2A, α1A, α1B, α2C. More potent 5HT2A antagonism, 5HT1A partial agonism, and α1 antagonism (relative to D2 partial agonism) than aripiprazole, proposed to reduce akathisia and enhance affective/cognitive effects. (1) ·
Phenothiazine D2 antagonist (5) ·
Serotonin releasing agent; monoamine reuptake inhibitor (1) ·
Serotonin/norepinephrine/dopamine releasing agent (3) ·
Thioxanthene D2 antagonist (1)
uses:
None (31) ·
Schizophrenia (FDA-approved 2015). Acute manic or mixed episodes of bipolar I disorder. Bipolar I depression (FDA-approved 2019). Adjunctive treatment of major depressive disorder (FDA-approved Dec 2022). (1) ·
Schizophrenia (FDA-approved 2015). Adjunctive treatment of major depressive disorder (2015). '''Agitation associated with dementia due to Alzheimer disease''' (FDA-approved May 2023, first agent specifically approved for this problem). Investigational for PTSD (combined with sertraline). (1) ·
Schizophrenia (FDA-approved Dec 2019). Bipolar depression as monotherapy or adjunct to lithium/valproate (FDA-approved Dec 2021). (1)
starting dose:
None (31) ·
42 mg PO once daily with food (no titration) (1) ·
Schizophrenia: 1 mg PO daily × 4 days, then 2 mg daily × 3 days, then 4 mg daily. MDD adjunct: 0.5-1 mg daily, increase to 2 mg max. AD agitation: 0.5 mg daily, titrate to 2-3 mg daily. (1) ·
Schizophrenia: 1.5 mg PO daily, increase to 1.5-6 mg as tolerated. Bipolar mania: 1.5 mg, may increase to 3-6 mg. Bipolar depression: 1.5 mg daily for 14 days, then 3 mg. MDD adjunct: 1.5 mg, may increase to 3 mg. (1)
preparations:
fda max:
onset:
duration:
halflife:
bioavailability:
pregnancy:
Showing below up to 34 results in range #1 to #34.